Sihuan Pharmaceutical Holdings Group (FRA:TEL1) Ending Cash Position : €462.0 Mil (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Ending Cash Position?

Sihuan Pharmaceutical Holdings Group's Ending Cash Position for the quarter that ended in Dec. 2024 was €462.0 Mil.

Sihuan Pharmaceutical Holdings Group's quarterly Ending Cash Position increased from Dec. 2023 (€485.3 Mil) to Jun. 2024 (€513.5 Mil) but then declined from Jun. 2024 (€513.5 Mil) to Dec. 2024 (€462.0 Mil).

Sihuan Pharmaceutical Holdings Group's annual Ending Cash Position declined from Dec. 2022 (€518.4 Mil) to Dec. 2023 (€485.3 Mil) and declined from Dec. 2023 (€485.3 Mil) to Dec. 2024 (€462.0 Mil).

Sihuan Pharmaceutical Holdings Group Ending Cash Position Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Ending Cash Position Chart

Sihuan Pharmaceutical Holdings Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

578.74

789.56

518.45

485.29

462.03

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															518.45	481.26	485.29	513.51	462.03

Sihuan Pharmaceutical Holdings Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sihuan Pharmaceutical Holdings Group's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	495.643	+	-33.617
	=	462.0

Sihuan Pharmaceutical Holdings Group's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	525.995	+	-63.969
	=	462.0

Sihuan Pharmaceutical Holdings Group Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sihuan Pharmaceutical Holdings Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (FRA:TEL1) » Definitions » Ending Cash Position

Traded in Other Exchanges

SHPHF:USA 00460:Hong Kong

Address

Zhubang 2000, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025

Website

https://www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.

Sihuan Pharmaceutical Holdings Group Headlines

No Headlines